Tuberculosis Drugs Market – Restraints
The increasing incidence of drug recall is a major factor restraining the market growth. Manufacturers of TB drug are facing challenges such as increasing product recalls owing to factors such as packaging or manufacturing flaws. For instance, in 2018, Sandoz recalled its batch of wrongly-packed tuberculosis (TB) drugs in India. Furthermore, in 2016, Novartis manufactured a drug Onecure which was recalled by the Philippines Food and Drug Administration for insufficient amount of rifampicin in the drug.
The high pricing of drugs is another factor restraining the growth of the market. Second line treatment drugs are highly priced compared to first line treatment with more side effects and high level toxicity.
Tuberculosis Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients